![$30 Million Government-Funded Cell Phone Radiation Study Shows Clear Evidence of Cancer $30 Million Government-Funded Cell Phone Radiation Study Shows Clear Evidence of Cancer](https://i.ntd.com/assets/uploads/2025/02/id1046105-cell-phone-radiation.png-900x506.webp)
The specific findings of the study, which was done on rodents and carefully adjusted so the results could easily be applied to humans (which is standard protocol with high-quality clinical studies done on rodents), found several forms of cancer in the male rodents, and DNA damage in both males and females. In the males, they mainly found two rare types of cancer: Schwannomas of the heart and gliomas of the brain. These same rare cancers have been found in epidemiological studies previously done on humans exposed to cell phone radiation. Gliomas are a particularly deadly form of cancer. All the tumors were in the male rats, but both the males and females showed indications of precancerous conditions and DNA damage. These multiple negative effects occurred in the exposure group, with no effects in the control group.
“Everyone expected this study to be negative,” said a senior government radiation official who asked to remain anonymous. This statement may explain why this massive, flawlessly designed, government-funded, government-executed study has since been swept under the rug and dismissed by all agencies involved, even after spending $30 million in taxpayer money to execute the study, for the sake of public health. Now the FCC and the FDA, and even the NTP itself, are significantly downplaying the results, stating that these results in rodents cannot necessarily be applied to humans. The whole study was designed and executed exactly so that the results could apply to humans.
According to a report on the FDA’s website, “After reviewing the study, we disagree, however, with the conclusions of their final report regarding ‘clear evidence’ of carcinogenic activity in rodents exposed to radiofrequency energy.”
The FDA is disagreeing with the verdict of a group of actual scientists and expert toxicologists, with no valid explanation for their opinion. Do you ever wonder if these agencies might be a little bit biased, or maybe even “bought out” by the industry itself?
This is just one of the thousands of studies that have shown the biological effects of electromagnetic fields (EMFs). With the dangers of EMFs becoming widely known, many attempts to prevent these harmful effects are being explored. There are blocking and shielding devices, passive devices like pendants and crystals, and impractical or impossible attempts to remove technology from your life.
The most comprehensive EMF protection solution is to generate a field that’s based on the infinitely varied and highly structured fields found in nature, but at a higher amplitude, so the body’s cells can perceive and entrain with this field over the harmful EMFs.
Blushield EMF Protection has been clinically proven to improve a wide variety of health markers, including cognitive function, blood glucose levels, sleep quality, and heart rate variability.
In fact, Blushield is the first EMF protection technology on the market to demonstrate a statistically significant improvement in the function of the body’s own voltage-gated calcium channels, which is the primary upstream mechanism of biological effects from EMFs, according to cutting edge research.
Go here to learn more about Blushield technology and how it can help us thrive in the modern world.
As an NTD reader, you get 10 percent off any home and portable Blushield device, automatically applied at checkout.
THIS CONTENT IS NOT INTENDED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS OR TREATMENT. NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE, OR DELAY IN SEEKING IT, BECAUSE OF SOMETHING YOU HAVE READ IN THIS PUBLICATION. NEVER RELY ON INFORMATION IN THIS PUBLICATION IN PLACE OF SEEKING PROFESSIONAL MEDICAL ADVICE. EPOCH HEALTH DOES NOT RECOMMEND OR ENDORSE ANY SPECIFIC TESTS, PRODUCTS, PROCEDURES, OPINIONS OR OTHER INFORMATION THAT MAY BE PROVIDED IN THIS PUBLICATION.